Edition:
United States

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

166.97USD
9 Dec 2016
Change (% chg)

$3.02 (+1.84%)
Prev Close
$163.95
Open
$166.85
Day's High
$169.18
Day's Low
$166.25
Volume
402,802
Avg. Vol
412,790
52-wk High
$210.26
52-wk Low
$147.73

SHPG.OQ

Chart for SHPG.OQ

About

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.... (more)

Overall

Beta: 1.44
Market Cap(Mil.): $50,424.49
Shares Outstanding(Mil.): 301.34
Dividend: 0.14
Yield (%): 0.48

Financials

  SHPG.OQ Industry Sector
P/E (TTM): 62.83 29.73 30.40
EPS (TTM): 2.66 -- --
ROI: 1.09 15.87 15.24
ROE: 2.09 16.99 16.58

Momenta's Humira biosimilar succeeds in key psoriasis study

U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

UPDATE 1-Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

Omega's Einhorn sees Trump's policies boosting stocks

NEW YORK U.S. stocks are poised to climb more in 2017 as the policies of Republican President-elect Donald Trump are likely to boost earnings, Steven Einhorn, vice chairman of Hedge fund Omega Advisors, said on Monday.

Nov 15 2016

UPDATE 1-Shire sees opportunity in Asia, aims to double revenue by 2020

* Sees opportunity as China opens consultation on key drugs list

Nov 11 2016

Shire sees opportunity in Asia, aims to double revenue by 2020

SINGAPORE, Nov 11 Shire, a specialist in rare diseases, aims to double Asian sales by 2020, as it targets markets including China, where it hopes to put its haemophilia drugs on a reimbursement list being updated this year for the first time since 2009.

Nov 11 2016

Shire slips on poor sales of hemophilia drugs

LONDON Shire reported a fall in third-quarter sales of hemophilia drugs acquired in its $32 billion Baxalta deal in June, resulting in a rare miss on both the top and bottom lines and sending its shares lower.

Nov 01 2016

UPDATE 2-Shire slips on poor sales of haemophilia drugs

* Shares recover some losses to trade down 1.5 pct (Adds quotes, reaction, updates shares)

Nov 01 2016

Fund manager notches first win in drug patent challenge campaign

A U.S. Patent and Trademark Office tribunal has invalidated most of Shire PLC's patent on its Gattex short bowel syndrome drug, handing hedge fund manager Kyle Bass his first victory in an ongoing campaign of challenging drug patents.

Oct 25 2016

BRIEF-Shire granted EU approval for pancreatic cancer combination therapy

* Granted eu marketing authorization of onivyde, in combination with 5-fluorouracil (5-fu) and leucovorin (lv),for treatment of metastatic adenocarcinoma of pancreas in adult patients who have progressed following gemcitabine-based therapy Source text for Eikon: Further company coverage: (Reporting By UK Bureau)

Oct 18 2016

Earnings vs. Estimates